Onychomysosis
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
O se atigilima na aafia i le Onychomysosis
O le vae o se tagata ua maua i fao fao fungal i le sefulu vaiaso i le kosi o vaila'au tu'u gutu terbinafine. Matau le fusi o le ola maloloina o fao i tua atu o fao o totoe ua pisia.
References
Systemic antifungals o togafitiga sili ona aoga. O su'esu'ega fa'ata'ita'i e fa'aalia ai fua faatatau o togafitiga fa'ama'i e pei ona taua i lalo: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . O le fa'amama fa'atasi fao e fa'atuputeleina atili ai le fua faatatau o togafitiga. Togafitiga fa'apitoa ile ciclopirox e le aoga; o lo'o i ai se fua fa'aletonu e sili atu i le 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onychomycosis ose faʻamaʻi pipisi e afaina ai fao. A mafua mai i dermatophytes, e taʻua o le tinea unguium. Onychomycosis e aofia ai faʻamaʻi pipisi e mafua mai i dermatophytes, fefete, ma limu. O se fa'afitauli fao e le mafua mai i se fa'ama'i fa'ama'i e ta'ua ole nail dystrophy. E ui lava e mafai ona aʻafia uma atigilima ma atigilima, o le onychomycosis o tamatamaivae e sili atu ona taatele. O lenei tusiga o loʻo faʻatalanoaina vaega eseese o toenail onychomycosis, e pei o lona aʻafiaga, ituaiga falemaʻi, laasaga, suʻesuʻega, ma togafitiga. E ui e le lamatia ai le ola, onychomycosis e mafai ona oʻo atu ai i faʻalavelave matuia e pei o le cellulitis, sepsis, faʻamaʻi ponaivi, faʻaleagaina o aano, ma le gau o fao.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine ose vaila'au e fa'afefe ai fa'ama'i pipisi e ala ile poloka ole squalene epoxidase. E aoga e tetee atu ai i le tele o ituaiga o sigi pa'u ma ua fa'amaonia mo le togafitia o fao fao pe a tago tautala. E ui o le tele o a'afiaga e pei o le ulu ma fa'afitauli o le manava e laiti ma e alu ese na'o latou, o suiga i le tofo (dysgeusia) e mafai ona fesuisuiai mai le vaivai i le ogaoga, o nisi taimi e o'o atu ai i le pa'u mamafa. O suiga tumau o le tofo e seasea ae ua lipotia.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onychomycosis o se faʻamaʻi pipisi e afaina ai fao. E tusa ma le 90% o fa'ama'i atigilima ma le 75% o fa'ama'i atigilima e mafua mai i sigi (Trichophyton mentagrophytes, Trichophyton rubrum) . O auga e aofia ai le liu lanu o fao, mafiafia, vavae ese mai le moega fao, ma le tupu tele. Togafitiga masani e aofia ai vailaʻau tuʻu gutu e pei o le terbinafine poʻo le itraconazole, faʻatasi ai ma togafitiga autu o se filifiliga mo mataupu mama ma feololo.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
O le vaila'au fa'ama'i fa'ama'i o le terbinafine e ave e le gutu e foliga mai e sili ona aoga ae o le terbinafine e feso'ota'i ma le a'afiaga o le ate.
Onychomysosis e tupu ile 10 pasene ole faitau aofa'i o tagata matutua, ma tagata matutua e sili atu ona a'afia. E sili atu ona afaina tane nai lo fafine. Onychomysosis o lo'o fa'atusalia le afa o fa'ama'i fao. O lona uiga o le faaletonu o atigivae e mafai foi ona sau mai mafuaaga e ese mai i le onychomycosis.
○ Togafitiga - Vailaau OTC
E faigata ona togafitia le onychomycosis i vailaʻau faʻapitoa ona e faigata i vailaʻau ona ati i atigilima mafiafia.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Togafitiga
O togafitiga umi e masani lava ona mana'omia se'iloga e aveese atoa le atigilima ua pisia.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer